Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

Overview

This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of IV peramivir compared to a standard 5 day course of oral oseltamivir in the treatment of pediatric subjects with acute uncomplicated influenza.

Full Title of Study: “A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 28, 2019

Interventions

  • Drug: Peramivir
  • Drug: Oseltamivir

Arms, Groups and Cohorts

  • Experimental: Peramivir (IV)
    • Subjects randomized to peramivir will receive an age appropriate single dose, diluted to a maximum volume of 100 mL in normal saline, administered as a short intravenous infusion over a minimum of 15 minutes. Subjects ≥12 years will receive a dose of 600 mg. Subjects <12 years will receive a dose of 12 mg/kg (to a maximum dose of 600 mg). Subjects < 6 months will receive a dose of 8 mg/kg.
  • Active Comparator: Oseltamivir
    • Subjects randomized to oral oseltamivir will receive an age appropriate dose twice daily for 5 days. Subjects ≥ 13 years will receive a 75mg dose administered as a capsule or oral suspension (twice daily for 5 days). Subjects < 13 years of age will receive a weight-based dose administered as a capsule or oral suspension (twice daily for 5 days).

Clinical Trial Outcome Measures

Primary Measures

  • Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events.
    • Time Frame: 14 days
    • Safety evaluation included assessment of Adverse Events (AEs).

Secondary Measures

  • Plasma Exposure of IV Peramivir as Measured by the Drug Concentration Over 6 Hours Post-dose
    • Time Frame: up to 6 hours post peramivir infusion
    • Up to 4 blood samples will be drawn, where possible: immediately following infusion and 30 to 60 mins, 1 to 3 hrs and 4 to 6 hrs post-infusions. AUC calculations were performed in Phoenix WinNonlin using the linear/log trapezoidal rule. AUC0-last was calculated between start of the infusion and the time of the last measurable concentration.
  • Time to Resolution of Fever
    • Time Frame: 14 days
    • Time for fever resolution based on subject diary record of temperature recorded twice daily. A subject had resolution of fever if he/she had oral temperature of < 99.4°F or an axillary temperature of < 98.4°F and no antipyretic medications were taken for ≥ 12 hours. The time to resolution of fever was estimated for each age group and overall using the Kaplan-Meier method with temperature and symptom relief medication information obtained from the Subject Diary data.
  • Time to Resolution of Influenza Symptoms
    • Time Frame: 14 days
    • Subjects or parents or caregivers were asked to provide an assessment of age-appropriate influenza symptoms on a 4-point severity scale (0,absent; 1, mild; 2, moderate; 3, severe) twice daily beginning before screening on Day 1 until symptoms resolved or until the last follow-up visit. Time to alleviation of symptoms was the number of hours from initiation of study drug until the start of the time period in which all age-appropriate symptoms of influenza were either absent or present at a level no greater than mild for at least 21.5 (24 – 10%) hours. Subjects who did not experience alleviation of symptoms were censored at the last observed symptom assessment.
  • Time to Reduction in Viral Shedding
    • Time Frame: 14 days
    • Assessment of viral shedding in bilateral, mid-nasal swab specimens taken at baseline and then on Day 3, 7 and 14.
  • Changes in Influenza Virus Titer in Nasopharyngeal Samples in Response to Treatment.
    • Time Frame: Change from baseline assessed on days 3, 7 and 14.
    • Change in influenza viral titers was defined as the time-weighted change from Baseline in log_10 tissue culture infective dose_50 (TCID50/mL) and was summarized for each treatment group.
  • Influenza-Related Complications Assessment.
    • Time Frame: 14 days
    • The investigator performed a full physical exam at baseline. At each follow-up visit, study personnel evaluated the subject for the presence of clinical signs and symptoms of the following influenza-related complications: sinusitis, otitis media, bronchitis, and pneumonia requiring antibiotic use, diagnosed after initiation of treatment.

Participating in This Clinical Trial

Key Inclusion Criteria:

1. Clinical signs and symptoms consistent with acute influenza infection consisting of an oral temperature ≥ 100°F (37.8°C) or rectal temperature ≥ 101.3ºF (≥ 38.5ºC) with at least one respiratory symptom (cough or rhinitis) OR Positive influenza determined by PCR or Rapid Antigen Test 2. Onset of symptoms no more than 72 hours before presentation for screening for subjects < 2 years old. Key Exclusion Criteria:

1. Pregnant or breast-feeding females 2. Development of symptoms while hospitalized 3. Presence of a chronic disease or illness that may indicate increased risk for influenza-related complications 4. Presence of immunocompromised status

Gender Eligibility: All

Minimum Age: 0 Days

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • BioCryst Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • John Vanchiere, MD, PhD, Principal Investigator, Chief, Pediatric Infectious Diseases, Louisiana State University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.